Jun 2026 (Q2 FY26) — Aug 5, 2026
PACS Group Q2 FY26 — Strong Revenue and Adjusted EBITDA Growth with Operational Improvements
Read the full callPACS Group (PACS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
PACS Group earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,428 | +9.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 7.7 | +1.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 76.4 | +49.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$45.85 −2.26% · −$1.06
Performance +274.0% 1Y
1Y: $12.26 on 17 Oct 2025 → $45.85. High $48.45 (10 Aug 2026), low $10.58 (14 Nov 2025).
- Previous close
- $46.91
- 52-week range
- $10.58 – $48.45
- One year
- +261.59%
Overview
- Symbol
- PACS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 12, 2026
PACS Group Q1 FY26 — Strong Operational Performance and Increased Adjusted EBITDA Guidance
Read the full callDec 2025 (Q4 FY25) — Feb 26, 2026
PACS Group Q4 FY25 — Record Performance and Strategic Integration
Read the full callEvery analysed call
PACS Group earnings calls (PACS)
Financials
What the filings say
Net profit, year on year: +50% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,026 | 1,208 | 1,277 | 1,309 | 1,345 | 1,358 | 1,420 | 1,428 |
| Expenses | 1,003 | 1,136 | 1,229 | 1,229 | 1,258 | 1,263 | 1,300 | 1,319 |
| Operating profit | 23 | 72 | 48 | 80 | 86 | 95 | 120 | 109 |
| Operating margin | 2.2% | 6.0% | 3.8% | 6.2% | 6.4% | 7.0% | 8.4% | 7.7% |
| Other income | 11 | -11 | -5 | -2 | -10 | -8 | -6 | -3 |
| Interest | 9 | 9 | 7 | 4 | 9 | 9 | 6 | 6 |
| Profit before tax | 34 | 61 | 43 | 79 | 76 | 87 | 114 | 106 |
| Tax rate | 51.8% | 40.9% | 33.6% | 35.2% | 31.4% | 31.1% | 29.1% | 27.9% |
| Net profit | 16 | 37 | 28 | 51 | 52 | 60 | 81 | 76 |
| EPS ($ per share) | 0.10 | — | 0.18 | 0.33 | 0.33 | — | 0.51 | 0.48 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 |
| Reserves | — | 96 | 118 | 310 |
| Total liabilities | — | 3,411 | 4,527 | 4,632 |
| Fixed assets | — | 578 | 991 | 1,201 |
| Total assets | — | 3,513 | 5,243 | 5,584 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | 93 | 64 | 367 | 404 |
| Cash from investing | -75 | -173 | -443 | -264 |
| Cash from financing | 12 | 130 | 117 | -69 |
| Net cash flow | 30 | 20 | 42 | 71 |
| Capital expenditure | -23 | -46 | -66 | -105 |
| Free cash flow | 70 | 18 | 301 | 299 |
PACS revenue by segment
| Segment | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|
| Reportable | 100% | 100% | 100% | 100% | 100% | 100% | +9.1% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
PACS operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Facilities | 321As of December 31, 2025, PACS operates 321 facilities across 17 states, caring for more than 31,700 patients daily and supported by over 47,000 dedicated team members.Source: earnings call transcript | 323As of March 31, 2026, PACS operated 323 facilities across 17 states with approximately 35,500 total beds, including roughly 32,700 skilled nursing beds and 2,700 assisted living beds -- across this platform, we are caring for approximately 31,900 patients daily.Source: earnings call transcript | 324As of June 30, PACS operated 324 health care facilities across 17 states with 35,631 total beds, including 32,790 skilled nursing beds and 2,841 assisted living beds.Source: earnings call transcript | +0.3% |
| Patients | 31.7K+As of December 31, 2025, PACS operates 321 facilities across 17 states, caring for more than 31,700 patients daily and supported by over 47,000 dedicated team members.Source: earnings call transcript | ~31.9KAs of March 31, 2026, PACS operated 323 facilities across 17 states with approximately 35,500 total beds, including roughly 32,700 skilled nursing beds and 2,700 assisted living beds -- across this platform, we are caring for approximately 31,900 patients daily.Source: earnings call transcript | 31.9K+Across this platform, our teams care for more than 31,900 patients each day, supported by approximately 48,000 employees.Source: earnings call transcript | — |
| Employees | 47K+As of December 31, 2025, PACS operates 321 facilities across 17 states, caring for more than 31,700 patients daily and supported by over 47,000 dedicated team members.Source: earnings call transcript | — | ~48KAcross this platform, our teams care for more than 31,900 patients each day, supported by approximately 48,000 employees.Source: earnings call transcript | — |
| Total operating beds | 35.379KToday, our portfolio includes 35,379 total operating beds, of which 32,854 are skilled nursing beds and 2,525 are assisted living beds, which span across 17 states, reflecting a scaled and geographically diversified footprint.Source: earnings call transcript | ~35.5KAs of March 31, 2026, PACS operated 323 facilities across 17 states with approximately 35,500 total beds, including roughly 32,700 skilled nursing beds and 2,700 assisted living beds -- across this platform, we are caring for approximately 31,900 patients daily.Source: earnings call transcript | 35.631KAs of June 30, PACS operated 324 health care facilities across 17 states with 35,631 total beds, including 32,790 skilled nursing beds and 2,841 assisted living beds.Source: earnings call transcript | — |
| Total operating beds Skilled Nursing | 32.854KToday, our portfolio includes 35,379 total operating beds, of which 32,854 are skilled nursing beds and 2,525 are assisted living beds, which span across 17 states, reflecting a scaled and geographically diversified footprint.Source: earnings call transcript | ~32.7KAs of March 31, 2026, PACS operated 323 facilities across 17 states with approximately 35,500 total beds, including roughly 32,700 skilled nursing beds and 2,700 assisted living beds -- across this platform, we are caring for approximately 31,900 patients daily.Source: earnings call transcript | 32.79KAs of June 30, PACS operated 324 health care facilities across 17 states with 35,631 total beds, including 32,790 skilled nursing beds and 2,841 assisted living beds.Source: earnings call transcript | — |
| Total operating beds Assisted Living | 2,525Today, our portfolio includes 35,379 total operating beds, of which 32,854 are skilled nursing beds and 2,525 are assisted living beds, which span across 17 states, reflecting a scaled and geographically diversified footprint.Source: earnings call transcript | 2,700As of March 31, 2026, PACS operated 323 facilities across 17 states with approximately 35,500 total beds, including roughly 32,700 skilled nursing beds and 2,700 assisted living beds -- across this platform, we are caring for approximately 31,900 patients daily.Source: earnings call transcript | 2,841As of June 30, PACS operated 324 health care facilities across 17 states with 35,631 total beds, including 32,790 skilled nursing beds and 2,841 assisted living beds.Source: earnings call transcript | +5.2% |
| Occupancy rate | 89.1%Total occupancy stands at 89.1% with our mature facilities delivering exceptional 94.9% occupancy, up from 94.4% last year.Source: earnings call transcript | 90.9%Total occupancy for all facilities for the quarter was 90.9%, compared to 89.2% in the prior year and continuing to significantly outpace the industry average of approximately 79%.Source: earnings call transcript | — | +1.8 pt |
| Occupancy rate Mature Facilities | 94.9%Total occupancy stands at 89.1% with our mature facilities delivering exceptional 94.9% occupancy, up from 94.4% last year.Source: earnings call transcript | 94.8%Our mature facilities remained highly stable, operating at 94.8% occupancy with skilled mix of 33% and which continues to reflect the strength and consistency of our longer-tenured operations.Source: earnings call transcript | 93.8%As expected, our occupancy increases as we move across these cohorts with new facilities occupancy at 78.7%, ramping facilities at 87.7% occupancy and mature facilities at 93.8% occupancy.Source: earnings call transcript | -1 pt |
| Occupancy rate Ramping facilities | — | 88.9%Our ramping facilities averaged 88.9% occupancy with skilled mix continuing to improve, reflecting ongoing operational progress as these facilities move toward mature performance levels.Source: earnings call transcript | 87.7%As expected, our occupancy increases as we move across these cohorts with new facilities occupancy at 78.7%, ramping facilities at 87.7% occupancy and mature facilities at 93.8% occupancy.Source: earnings call transcript | -1.2 pt |
| Occupancy rate New facilities | — | 82.7%Our new facilities averaged 82.7% occupancy, with skilled mix of 26.5%, reflecting the early stages of integration and stabilization as these facilities continue progressing towards mature performance levels.Source: earnings call transcript | 78.7%As expected, our occupancy increases as we move across these cohorts with new facilities occupancy at 78.7%, ramping facilities at 87.7% occupancy and mature facilities at 93.8% occupancy.Source: earnings call transcript | -4 pt |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
120 filings between Nov 24, 2025 and Oct 16, 2026.
Open market
decisions to buy or sellPurchases
$500.0K
1 purchase by 1 insider
Sales
$92.34M
76 sales by 6 insiders
96% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 33
- Award — granted as compensation
- 8
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Hancock Mark | — | $40.97M | Sep 15, 2026 |
| Murray Jason Hulse | — | $33.77M | Oct 16, 2026 |
| Jergensen Joshua | — | $8.38M | Oct 14, 2026 |
| MITCHELL JOHN TODD | — | $7.79M | May 18, 2026 |
| Lewis Michelle Renee | — | $1.28M | Jul 6, 2026 |
| Dilsaver Evelyn S | $500.0K | — | Nov 24, 2025 |
| Conway Patrick Hugh | — | $155.3K | Aug 14, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 16, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 8,462 | $402.9K |
| Oct 15, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 4,633 | $211.3K |
| Oct 15, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 77,540 | $3.68M |
| Oct 15, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 3,062 | $147.3K |
| Oct 15, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 24,800 | $1.16M |
| Oct 14, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 232 | $10.4K |
| Oct 14, 2026 | Jergensen Joshua President & COO | Sale 10b5-1 plan | 40,000 | $1.78M |
| Oct 7, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 717 | $30.5K |
| Oct 6, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 7,222 | $315.1K |
| Oct 6, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 28,753 | $1.24M |
| Oct 5, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 24,224 | $1.03M |
| Oct 2, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 23,456 | $999.1K |
| Oct 2, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 2,596 | $108.5K |
| Oct 1, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 33,032 | $1.36M |
| Sep 16, 2026 | Jergensen Joshua President & COO | Sale 10b5-1 plan | 36,502 | $1.57M |
| Sep 16, 2026 | Jergensen Joshua President & COO | Sale 10b5-1 plan | 3,498 | $152.6K |
| Sep 15, 2026 | Hancock Mark Director | Sale 10b5-1 plan | 104,132 | $4.38M |
| Sep 15, 2026 | Hancock Mark Director | Sale 10b5-1 plan | 30,466 | $1.31M |
| Sep 15, 2026 | Hancock Mark Director | Sale 10b5-1 plan | 21,084 | $922.4K |
| Sep 14, 2026 | Hancock Mark Director | Sale 10b5-1 plan | 137,684 | $6.13M |
| Sep 14, 2026 | Hancock Mark Director | Sale 10b5-1 plan | 6,634 | $297.9K |
| Sep 14, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 317 | $14.3K |
| Sep 11, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 10,529 | $476.2K |
| Sep 10, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 8,771 | $396.1K |
| Sep 9, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 4,758 | $206.1K |
| Sep 8, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 3,056 | $130.8K |
| Sep 8, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 21,001 | $915.5K |
| Sep 4, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 243 | $10.5K |
| Sep 4, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 22,829 | $974.4K |
| Sep 3, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 19,315 | $821.5K |
| Sep 3, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 858 | $37.0K |
| Sep 2, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 17,435 | $745.9K |
| Sep 2, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 6,348 | $275.3K |
| Sep 1, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 1,368 | $58.9K |
| Sep 1, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 22,789 | $965.2K |
| Aug 21, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 31,654 | $1.38M |
| Aug 21, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 27,590 | $1.22M |
| Aug 20, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 13,879 | $621.3K |
| Aug 20, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 77,427 | $3.39M |
| Aug 19, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 84,650 | $3.75M |
| Aug 19, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 67 | $3.0K |
| Aug 18, 2026 | Hancock Mark Director | Gift | 88,000 | $0 |
| Aug 18, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 66,797 | $2.95M |
| Aug 17, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 74,844 | $3.31M |
| Aug 17, 2026 | Murray Jason Hulse Co-Founder, CEO & Chairman | Sale 10b5-1 plan | 9,758 | $422.9K |
| Aug 14, 2026 | Conway Patrick Hugh Director | Sale | 3,497 | $155.3K |
| Aug 12, 2026 | Jergensen Joshua President & COO | Sale 10b5-1 plan | 3,625 | $161.4K |
| Aug 12, 2026 | Jergensen Joshua President & COO | Sale 10b5-1 plan | 36,375 | $1.66M |
| Jul 15, 2026 | Jergensen Joshua President & COO | Sale 10b5-1 plan | 233 | $10.7K |
| Jul 15, 2026 | Jergensen Joshua President & COO | Sale 10b5-1 plan | 32,327 | $1.46M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for PACS Group, Inc.
Free account. Everything above stays public.
Write why you follow PACS Group, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading